| Literature DB >> 24662035 |
Abstract
Using Alzheimer's disease as a case study, this review argues that it might be time to consider a new paradigm in medical research and drug discovery. The existing framework is overly dependent on often unvalidated animal models, particularly transgenic mice. Translational success remains elusive and costly late-stage drug failure is common. The conventional paradigm tends to overlook species differences and assumes that animal-based findings are generally applicable to humans. Could pathways-based research using advanced human-specific models probed with new tools, including those of systems biology, take centre stage? The current transition in chemical toxicology to a 21st-century paradigm could be a model for health research, with probable medical and economic benefits.Entities:
Mesh:
Year: 2014 PMID: 24662035 DOI: 10.1016/j.drudis.2014.03.013
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851